Clinical trialsCompany release

NeOnc says NEO100 met Phase 2a endpoint in recurrent IDH1-mutant glioma, but criteria diverge

🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Tue 17 Nov 2026

A corporate deck reports 48.9% six-month PFS by RANO 2.0 in 24 patients, yet the protocol-specified RANO criteria gave 25.8%, with an unlocked database.

NeOnc Technologies (NASDAQ: NTHI) has reported results from a Phase 2a study of intranasal NEO100, an ultra-pure form of perillyl alcohol, in recurrent IDH1-mutant grade III–IV glioma. The data appear in a corporate presentation rather than a full publication or regulatory document, and the company says the study met its primary endpoint.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Neonc Technologies Holdings, Inc. ↗

Article written by VigiEye from the official source (Neonc Technologies Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.